mdt

The bank sees 2012 EPS of $3.47, in line with consensus estimates, and 2013 EPS of $3.86, vs. consensus estimates of $3.80 per share.

Medtronic has a potential upside of 12.1% based on a current price of $38.72 and an average consensus analyst price target of $43.39.

Citigroup said it expects upside for Medtronic's (NYSE:MDT) Cardiovascular business and maintained its buy rating and $46 price target.

The board of directors for Medtronic, Inc.

On Wednesday, MDT said the FDA sent the company a letter in Q3 of fiscal 2011 declining to approve its Amplify rhBMP-2 Matrix bone graft material without additional information from MDT, Reuters reports.

MDT did not say what additional information the FDA sought but said that the company was continuing to seek FDA approval for the product.

Medtronic (MDT) is lower after it said the FDA rejected its Amplify product, which aims to use a protein to stimulate bone growth and relieve low back pain.

Morgan Stanley adjusted its 2011 and 2012 EPS estimates for Medtronic (NYSE:MDT) and maintained its equal-weight rating on the stock. The bank now sees 2011 EPS of $3.39, up from $3.37 per share, and 2012 EPS of $3.62, down from $

The company sees 2011 EPS estimates to $3.38 to $3.40, from $3.38 to $3.44 per share, vs.

Medtronic (NYSE:MDT) reported Q3 EPS of $0.86, ahead of consensus estimates of $0.84 per share. Revenues for the quarter rose 3% year-over-year to $3.96 billion, missing consensus estimates of $3.97 billion.

MDT had earlier made corrections to the labels as a response to the occurrence of pocket fills, or the inadvertent injection of all or some of the prescribed drug into the patient's subcutaneous tissue, during a refill of the insu

"Medtronic (MDT) announced today that the U.S. Food and Drug Administration (FDA) has classified the corrections being made to the labels of the company's SynchroMed II or SynchroMed EL Implantable Infusion Pump as a Class I recal

This is what's in the news for Tuesday, January 18th. Bloomberg reports that Apple (AAPL) CEO Steve Jobs announced a leave of absence, he reportedly has had trouble maintaining his weight as he has been undergoing cancer treat

CEO Bill Hawkins said he sees less pricing pressure on Medtronic products and more stability for the company's downtrodden spin business.

The comments came at a Goldman Sachs conferece.

Medtronic shares are up 0.11%, or $0.04, to $36.53.

Shares of Medtronic (MDT) are up fractionally in afternoon trading after the company's outgoing chief executive said he sees better days ahead for the medical device maker, Reuters reported.

Two senators are making inquiries about the experimental use of a Medtronic (MDT) product in spinal surgeries performed on veterans and soldiers at the Walter Reed Army Medical Center from 2002 to 2004, according to the New York T